JP Patent

JP2016074700A — ４−アミノキノリン−３−カルボニトリルを使用するイマチニブ耐性白血病の処置

Assigned to Wyeth LLC · Expires 2016-05-12 · 10y expired

What this patent protects

【課題】イマチニブ耐性白血病の処置のための方法の提供。【解決手段】治療上有効な量の下記式で表される、４−［（２，４−ジクロロ−５−メトキシ−フェニル）アミノ］−６−メトキシ−７−［３−（４−メチル−１−ピペラジニル）プロポキシ］−３−キノリンカルボニトリルを含む医薬組成物。【選択図】なし

USPTO Abstract

【課題】イマチニブ耐性白血病の処置のための方法の提供。【解決手段】治療上有効な量の下記式で表される、４−［（２，４−ジクロロ−５−メトキシ−フェニル）アミノ］−６−メトキシ−７−［３−（４−メチル−１−ピペラジニル）プロポキシ］−３−キノリンカルボニトリルを含む医薬組成物。【選択図】なし

Drugs covered by this patent

bosutinib-monohydrate (BOSUTINIB MONOHYDRATE)

Patent Metadata

Patent number: JP2016074700A
Jurisdiction: JP
Classification: —
Expires: 2016-05-12
Drug substance claim: No
Drug product claim: No
Assignee: Wyeth LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.